Details of the Drug-Related molecule(s) Interaction Atlas

General Information of DTT (ID: TTW20TU)

• DTT Name: TRAIL receptor 2 (TRAIL-R2) DTT Info
• Gene Name: TNFRSF10B

Molecule-Related Drug & Molecule List

8 Clinical Trial Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Conatumumab	DM2UOSN	Colorectal cancer	2B91.Z	Phase 2	[1]
Lexatumumab	DMOS5JZ	Solid tumour/cancer	2A00-2F9Z	Phase 2	[2]
Anti-DR5 cells	DMYKZB3	Hepatocellular carcinoma	2C12.02	Phase 1/2	[3]
BI 905711	DME9NYV	Solid tumour/cancer	2A00-2F9Z	Phase 1	[4]
DS-8273	DMJPUDW	Colorectal cancer	2B91.Z	Phase 1	[5]
GEN1029	DMV8IWJ	Solid tumour/cancer	2A00-2F9Z	Phase 1	[6]
IGM-8444	DMFJXDZ	Hematologic tumour	2B33.Y	Phase 1	[7]
INBRX-109	DMUNSPI	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]

3 Discontinued Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RhApo2L/TRAIL	DMIAZJ9	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1/2	[1]
HGS-TR2J	DM0W2TA	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[9]
LBY-135	DMSRD5U	Solid tumour/cancer	2A00-2F9Z	Discontinued in Phase 1	[10]

2 Investigative Drug(s) Transported by This DTP

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AD5-10	DMV48L3	Solid tumour/cancer	2A00-2F9Z	Investigative	[11]
DR-5/DR-4 cross reactive mabs	DMX2TZD	Solid tumour/cancer	2A00-2F9Z	Investigative	[11]

References

• [1] Clinical pipeline report, company report or official report of Amgen (2009).
• [2] National Cancer Institute Drug Dictionary (drug id 528015).
• [3] ClinicalTrials.gov (NCT03638206) Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies
• [4] Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist. Mol Cancer Ther. 2021 Jan;20(1):96-108.
• [5] First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors. Invest New Drugs. 2017 Jun;35(3):298-306.
• [6] National Cancer Institute Drug Dictionary (drug name Tilogotamab).
• [7] Clinical pipeline report, company report or official report of IGM Biosciences.
• [8] Clinical pipeline report, company report or official report of Inhibrx.
• [9] Enhancement of Glioma Radiation Therapy and Chemotherapy Response with Targeted Antibody Therapy Against Death Receptor 5. Int J Radiat Oncol Biol Phys. 2008 June 1; 71(2): 507-516.
• [10] Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors. Invest New Drugs. 2014 Feb;32(1):135-44.
• [11] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1880).